U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122895) titled 'Sex Differences in NMDA-enhancing Treatment of Schizophrenia' on Aug. 08.
Brief Summary: Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms. This study aims to examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: NMDAE
Use of an NMDA enhancer for the treatment of negative symptoms
DRUG: Placebo ...